Therapeutics Startups
44 companies tagged Therapeutics, with their investors and founders.
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.
11 investors
ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.
7 investors
Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
7 investors
Kopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.
6 investors
Persist AI provides AI-driven formulation development services for pharmaceutical compounds, combining robotic lab automation with machine learning models to accelerate drug formulation optimization and reduce time-to-market.
6 investors
Granza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.
5 investors
Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.
5 investors
Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.
4 investors
EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
4 investors
FinalDose develops a programmable DNA-targeting molecule designed to recognize and destroy cells carrying specific genetic sequences, with initial applications in oncology across cancer types.
4 investors
Promakhos Therapeutics develops immunomodulatory therapies to restore immune system balance and reduce chronic inflammation in diseases like Crohn's disease, ankylosing spondylitis, and psoriasis. The company targets patients with inflammatory diseases who do not benefit from current immunosuppressive treatments.
4 investors
Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.
4 investors
Abalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning. The company uses large-scale biological measurement platforms and AI-powered sequence analysis to discover functional antibody drugs for pharmaceutical and biotechnology applications.
3 investors
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
3 investors
Catena develops a conjugation platform for antibody-drug conjugates (ADCs) and multi-payload conjugates used in oncology for solid tumors. The company's technology enables therapeutic structures that deliver dual payloads to cancer targets.
3 investors
Equator Therapeutics develops first-in-class drugs targeting mitochondrial thermogenesis to treat obesity and metabolic disorders by restoring the body's natural heat production mechanism. The company uses bioelectricity research and high-throughput assays to identify selective activators of thermogenic compounds in mitochondria.
3 investors
Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
3 investors
Nanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.
3 investors
Sequence Bio discovers genetic causes of disease within Newfoundland and Labrador's founder population to develop breakthrough treatments, diagnostics, and preventions. The company focuses on translational biology and genetics research for patients globally.
3 investors
Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.
3 investors
Yemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.
3 investors
Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.
2 investors
Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.
2 investors
Gerostate Alpha creates drug candidates targeting age-related conditions and long-term illnesses.
2 investors